戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 val analysis, and reduction in the number of antiglaucoma medications.
2  therefore represents a potential target for antiglaucoma medications.
3 ar pressure, which responded well to topical antiglaucoma medications.
4 ucoma medications in the absence of systemic antiglaucoma medications.
5 d controlled 12 months after surgery without antiglaucoma medications.
6 d procedures, and 4698 eyes (93.6%) received antiglaucoma medications.
7 ch the target IOP and decrease the number of antiglaucoma medications.
8 patient was managed with corticosteroids and antiglaucoma medications.
9 -related procedures, and nearly all received antiglaucoma medications.
10 ied success was IOP <=18, 15 or 12 mmHg with antiglaucoma medications.
11 p = 0.29), but there was a difference in the antiglaucoma medications (1.58 (+/-1.5) and 0.53 (+/-1.0
12 defined as IOP </= 12 mm Hg without and with antiglaucoma medications (absolute success and qualified
13 ded intraocular pressure (IOP) and number of antiglaucoma medications after 6 weeks with three, six,
14                  Intraocular pressure (IOP), antiglaucoma medication (AGM) burden, best-corrected vis
15  (IOP), best-corrected visual acuity (BCVA), antiglaucoma medication (AGM) changes and surgical succe
16 mHg, > 18 mmHg, or increase in the number of antiglaucoma medications (AGMs) used (after the first po
17  less than or equal to 21 or 16 mmHg without antiglaucoma medications (AGMs), and qualified when AGMs
18 st-corrected visual acuity (BCVA), number of antiglaucoma medications (AGMs), complications, and fail
19 ine significant differences in the number of antiglaucoma medications (AGMs), intraocular pressure (I
20 eline with (qualified) or without (complete) antiglaucoma medications (AGMs).
21 essure (IOP) control and the requirement for antiglaucoma medications (AGMs).
22             The treatment algorithm included antiglaucoma medications and cycloplegics as first-line
23  pressure reduction of at least 20%, without antiglaucoma medication, and without any additional inte
24 ressants, antiepileptic medications, topical antiglaucoma medications, and chemotherapeutic/immunosup
25 ere no differences in IOP, vision, number of antiglaucoma medications, and complications between grou
26 ures included changes in mean IOP, number of antiglaucoma medications, and needling and complication
27 ostoperative complications, and reduction in antiglaucoma medications, assessed up to 24 weeks.
28 ine IOP was 17.9 +/- 3.3 mm Hg and number of antiglaucoma medications at baseline was 2.0 +/- 1.0.
29 uctions in the proportion of participants on antiglaucoma medications at endpoint.
30                 Fifty-two percent were on no antiglaucoma medications at last follow-up.
31 oma medications to 9.6 +/- 2.7 mm Hg with no antiglaucoma medications at the final visit (P < .001 an
32 tions to 13.6 +/- 3.2 mm Hg with 0.2 +/- 0.5 antiglaucoma medications at the last visit (P < .001 and
33                    The IOP and the number of antiglaucoma medications before and after the procedure,
34 ially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on
35 outcomes included reduction in the number of antiglaucoma medications, complete and qualified success
36                         The median number of antiglaucoma medications decreased from 2 (range 0-4) to
37                                The number of antiglaucoma medications did not change in both groups (
38                                    Number of antiglaucoma medications did not change.
39 ion of IOP of >3 mm Hg and 20% and number of antiglaucoma medications equal to or less than baseline.
40 rol group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients u
41 al field (VF) mean deviation (MD), number of antiglaucoma medications, history of glaucoma surgery, a
42  least 1 week apart) with or without topical antiglaucoma medications in the absence of systemic anti
43 y, intraocular pressure (IOP), the number of antiglaucoma medications, IOP control and trabeculectomy
44              The effects of preservatives of antiglaucoma medications on corneal surface and tear fun
45 01), needling (P < 0.001), and postoperative antiglaucoma medications (P < 0.001) were associated wit
46 tatistically significant decrease in IOP and antiglaucoma medications (p = < 0.01).
47    Topical treatments-including antibiotics, antiglaucoma medications, preservatives, contact lens so
48 plication for intracameral administration of antiglaucoma medications, this study, for the first time
49              Main outcome measures were IOP, antiglaucoma medications, time to failure, and Kaplan-Me
50 ved from 21.9 +/- 7.9 mm Hg with 2.7 +/- 0.8 antiglaucoma medications to 13.6 +/- 3.2 mm Hg with 0.2
51 ved from 23.3 +/- 4.9 mm Hg with 2.6 +/- 0.7 antiglaucoma medications to 9.6 +/- 2.7 mm Hg with no an
52 ithout and qualified irrespective of topical antiglaucoma medication use.
53 dary outcome measures included the number of antiglaucoma medications, visual acuity (VA), and postop
54                                           An antiglaucoma medication was prescribed with a good lower
55 as 5.64 +/- 4.05 mmHg, the mean reduction of antiglaucoma medications was 1.00 +/- 0.85, and the mean
56                           The mean number of antiglaucoma medications was significantly reduced from
57  pressure (IOP), IOP reduction and number of antiglaucoma medications were compared between eyes with
58                                         Mean antiglaucoma medications were significantly reduced (P <
59  number of recent publications document that antiglaucoma medications with a long duration of action
60 32 contralateral glaucomatous eyes receiving antiglaucoma medications without any previous glaucoma s